Arbutus ends development of COVID, hepatitis b candidates

seekingalpha2023-09-12

Arbutus Biopharma (NASDAQ:ABUS) has pulled the plug on development of AB-343 and AB-161 for, respectively, COVID-19 and hepatitis B virus. AB-343 was an oral SARS-CoV-2 Mpro inhibitor and AB-161, an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2366026329?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295693740/image_1295693740.jpg","is_english":true,"pubTime":"2023-09-12 05:32","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2366026329","market":"us","top_or_hot":-1,"title":"Arbutus ends development of COVID, hepatitis b candidates","media":"seekingalpha","content":"<div>\n<p>Arbutus Biopharma (NASDAQ:ABUS) has pulled the plug on development of AB-343 and AB-161 for, respectively, COVID-19 and hepatitis B virus. AB-343 was an oral SARS-CoV-2 Mpro inhibitor and AB-161, an ...</p>\n\n<a href=\"https://seekingalpha.com/news/4010775-arbutus-ends-development-of-covid-hepatitis-b-candidates\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus ends development of COVID, hepatitis b candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus ends development of COVID, hepatitis b candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-12 05:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4010775-arbutus-ends-development-of-covid-hepatitis-b-candidates><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arbutus Biopharma (NASDAQ:ABUS) has pulled the plug on development of AB-343 and AB-161 for, respectively, COVID-19 and hepatitis B virus. AB-343 was an oral SARS-CoV-2 Mpro inhibitor and AB-161, an ...</p>\n\n<a href=\"https://seekingalpha.com/news/4010775-arbutus-ends-development-of-covid-hepatitis-b-candidates\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://seekingalpha.com/news/4010775-arbutus-ends-development-of-covid-hepatitis-b-candidates","article_id":"2366026329","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295693740/image_1295693740.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2366026329","pubTimestamp":1694467970,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Arbutus Biopharma  has pulled the plug on development of AB-343 and AB-161 for, respectively, COVID-19 and hepatitis B virus. AB-343 was an oral SARS-CoV-2 Mpro inhibitor and AB-161, an oral RNA destabilizer. As a result of discontinuing both programs, Arbutus'  cash runway is extended to Q3 2025.  The company noted that it is on schedule to report results in Q4 from a phase 2a clinical trial with imdusiran and Vaccitech's  VTP-300 in patients with chronic HBV.   More on Arbutus Biopharma  Arbutus Biopharma appoints Karen Sims as chief medical officer Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","ABUS":"Arbutus Biopharma Corporation"},"translate_title":"杨梅终止COVID、乙型肝炎候选物的发育","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1,"VACC":1},"content_text":"Arbutus Biopharma (NASDAQ:ABUS) has pulled the plug on development of AB-343 and AB-161 for, respectively, COVID-19 and hepatitis B virus. AB-343 was an oral SARS-CoV-2 Mpro inhibitor and AB-161, an oral RNA destabilizer. As a result of discontinuing both programs, Arbutus' (ABUS) cash runway is extended to Q3 2025.  The company noted that it is on schedule to report results in Q4 from a phase 2a clinical trial with imdusiran and Vaccitech's (VACC) VTP-300 in patients with chronic HBV.   More on Arbutus Biopharma  Arbutus Biopharma appoints Karen Sims as chief medical officer Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2366026329"}